Stock DNA
Pharmaceuticals & Biotechnology
MXN 7,082 Million (Micro Cap)
12.00
NA
0.02%
-0.26
20.04%
2.67
Revenue and Profits:
Net Sales:
1,195 Million
(Quarterly Results - Mar 2026)
Net Profit:
135 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.07%
0%
-4.07%
6 Months
3.51%
0%
3.51%
1 Year
31.08%
0%
31.08%
2 Years
55.22%
0%
55.22%
3 Years
40.54%
0%
40.54%
4 Years
9.26%
0%
9.26%
5 Years
81.54%
0%
81.54%
Medica Sur SA de CV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.70%
EBIT Growth (5y)
3.90%
EBIT to Interest (avg)
8.23
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
1.32
Tax Ratio
29.58%
Dividend Payout Ratio
23.45%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
25.99%
ROE (avg)
16.72%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
2.44
EV to EBIT
7.50
EV to EBITDA
5.94
EV to Capital Employed
2.85
EV to Sales
1.21
PEG Ratio
0.26
Dividend Yield
0.02%
ROCE (Latest)
38.00%
ROE (Latest)
20.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,194.70
1,222.70
-2.29%
Operating Profit (PBDIT) excl Other Income
242.20
251.40
-3.66%
Interest
25.40
27.20
-6.62%
Exceptional Items
0.00
0.00
Consolidate Net Profit
134.50
138.50
-2.89%
Operating Profit Margin (Excl OI)
160.50%
164.20%
-0.37%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -2.29% vs 3.62% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -2.89% vs 12.15% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,788.90
4,402.80
8.77%
Operating Profit (PBDIT) excl Other Income
1,040.20
882.30
17.90%
Interest
163.20
123.80
31.83%
Exceptional Items
0.80
-74.40
101.08%
Consolidate Net Profit
540.20
422.50
27.86%
Operating Profit Margin (Excl OI)
175.40%
156.30%
1.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 8.77% vs 6.61% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 27.86% vs -24.27% in Dec 2024
About Medica Sur SA de CV 
Medica Sur SA de CV
Pharmaceuticals & Biotechnology
Medica Sur SAB de CV is a Mexico-based company primarily engaged in the healthcare sector. The Company manages hospitals, emergency and diagnostic centers, medical laboratories, organ and blood banks, as well as an accommodation place. It provides medical services within various specializations, such as anatomic pathology, cardiology, gynecology and obstetrics, neonatology, neurophysiology, odontology, oncology, ophthalmology, orthopedics, otolaryngology, pediatrics, radiology and imaging, as well as radiosurgery. In addition, the Company offers medical tourism services and distributes drugs. It forms a part of Mayo Clinic Care Network. The Company operates through a range of subsidiaries, such as Corporacion de Atencion Medica SA de CV, El Portal Medico SA de CV, Servicios de Administracion Hospitalaria SA de CV and Telemed SA de CV. The Company is owned by Neuco SA de CV.
Company Coordinates 
Company Details
Puente de Piedra 150, Col. Toriello Guerra TLALPAN None : 14050
Registrar Details






